Use of DNA methyltransferase inhibitor and poly(adenosine diphosphate ribose) polymerase inhibitor (PARPi) in the treatment of PARPi-resistant, high-grade serous ovarian cancer

被引：0
作者：
Shafa, Anousheh [1 ]
Hou, Xiaonan [1 ]
Wang, Liewei [1 ]
Weroha, S. John [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
GYNECOLOGIC ONCOLOGY | 2024年 / 190卷
关键词：
D O I：
10.1016/j.ygyno.2024.07.332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1275
引用
收藏
页码：S229 / S229
页数：1
相关论文
共 50 条
  • [41] Use of poly (adp-ribose) polymerase inhibitors (PARPi) in metastatic castration resistant prostate cancer (mCRPC) patients stratified by homologous recombination repair mutations
    Thomas, Roby Antony
    Vasudevan, Anupama
    Blanc, Simon
    Choksi, Rushir J.
    English, Sandy
    Aton, Lindsay
    Tierno, Marni Brisson
    Gart, Mike
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] DNA repair status of high-grade serous ovarian cancer change in a treatment course
    Takaya, Hisamitsu
    Nakai, Hidekatsu
    Sakai, Kazuko
    Nishio, Kazuto
    Matsumura, Noriomi
    CANCER SCIENCE, 2022, 113 : 363 - 363
  • [43] Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
    Vendrell, Julie A.
    Ban, Iulian O.
    Solassol, Isabelle
    Audran, Patricia
    Cabello-Aguilar, Simon
    Topart, Delphine
    Lindet-Bourgeois, Clothilde
    Colombo, Pierre-Emmanuel
    Legouffe, Eric
    D'Hondt, Veronique
    Fabbro, Michel
    Solassol, Jerome
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (18)
  • [44] Integrated efficacy and safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC)
    Oaknin, A.
    Oza, A.
    Tinker, A. V.
    Ray-Coquard, I.
    Coleman, R.
    O'Malley, D.
    Shapira-Frommer, R.
    Leary, A.
    Chen, L. M.
    Provencher, D.
    Ma, L.
    Brenton, J.
    Balmana, J.
    Giordano, H.
    Maloney, L.
    Goble, S.
    Rolfe, L.
    McNeish, I.
    Swisher, E.
    Kristeleit, R. S.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S95 - S95
  • [45] Costs and benefits of tumor testing for BRCA mutations in high-grade serous ovarian cancer as a companion diagnostic for PARP inhibitor treatment
    Kwon, J. S.
    Tinker, A. V.
    Karsan, A.
    Schrader, K. A.
    Sun, S.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 177 - 177
  • [46] Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
    Kanakkanthara, Arun
    Hou, Xiaonan
    Ekstrom, Thomas L.
    Zanfagnin, Valentina
    Huehls, Amelia M.
    Kelly, Rebecca L.
    Ding, Husheng
    Larson, Melissa C.
    Vasmatzis, George
    Oberg, Ann L.
    Kaufmann, Scott H.
    Mansfield, Aaron S.
    Weroha, S. John
    Karnitz, Larry M.
    CANCER RESEARCH, 2022, 82 (02) : 307 - 319
  • [47] Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
    Ihnen, Maike
    Eulenburg, Christine Zu
    Kolarova, Teodora
    Qi, Jing Wei
    Manivong, Kanthinh
    Chalukya, Meenal
    Dering, Judy
    Anderson, Lee
    Ginther, Charles
    Meuter, Alexandra
    Winterhoff, Boris
    Jones, Sian
    Velculescu, Victor E.
    Venkatesan, Natarajan
    Rong, Hong-Mei
    Dandekar, Sugandha
    Udar, Nitin
    Jaenicke, Fritz
    Los, Gerrit
    Slamon, Dennis J.
    Konecny, Gottfried E.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (06) : 1002 - 1015
  • [48] Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
    Hinchcliff, Emily
    Westin, Shannon Neville
    Dal Molin, Graziela
    LaFargue, Christopher J.
    Coleman, Robert L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (05) : 956 - 968
  • [49] First-in-human, phase 1/2 study of GSK4524101, an oral DNA polymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors
    Samnotra, Vivek
    Moroz, Veronica
    Shtessel, Luda
    Kuchimanchi, Mita
    Hanafin, Patrick
    Pannirselvam, Malar
    Bhaskar, Aishwarya
    Liu, Andrew
    Yuzugullu, Haluk
    Barve, Minal
    Sommerhalder, David
    Yap, Timothy
    Sanicola-Nadel, Michele
    CANCER RESEARCH, 2024, 84 (07)
  • [50] Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines
    Fleury, Hubert
    Carmona, Euridice
    Morin, Vincent G.
    Meunier, Liliane
    Masson, Jean-Yves
    Tonin, Patricia N.
    Provencher, Diane
    Mes-Masson, Anne-Marie
    ONCOTARGET, 2017, 8 (25) : 40152 - 40168
12345